sicklecellanemianews10h
Most patients free of vaso-occlusive crises for years after Casgevy dose
Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...
Vertex reports positive long-term data for Casgevy
Vertex Pharmaceuticals (NASDAQ:VRTX) presented positive long-term data for its gene therapy Casgevy and issued a business ...
TipRanks on MSN4d
Vertex Pharmaceuticals presents long-term data on CASGEVY at ASH
Vertex Pharmaceuticals (VRTX) announced longer-term data for CASGEVY from global clinical trials in people with severe sickle ...
Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy
Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of ...
FiercePharma1d
Vertex, Saudi Arabia ink memorandum of understanding to boost local gene therapy manufacturing
Two Saudi Arabian agencies signed on with Vertex Pharmaceuticals to help boost the countr | The Vertex agreement is part of ...
Business Wire4d
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trial ...
BioPharma Dive3d
Gene therapy uptake in sickle cell stays slow, despite patient interest
A lengthy treatment process, coupled with weighty risks for recipients to consider, has resulted in plodding adoption of ...
BioSpace7d
Bluebird, Vertex/CRISPR’s SCD Gene Therapies Get New CMS Payment Model
The payment scheme will tie gene therapy payments to improvements in health outcomes—and could potentially boost the uptake ...
3 of the Best Growth Stocks You Can Buy for Less than $100
It's getting harder these days to find great growth stocks trading for less than $100 a share. It almost seems like a higher ...
Seeking Alpha3d
Vertex reports positive long-term data for Casgevy
Vertex Pharmaceuticals (NASDAQ:VRTX) presented positive long-term data for its gene therapy Casgevy and issued a business update on the product. The data showed 93% of treated patients ...
Business Insider4d
Vertex Pharmaceuticals presents long-term data on CASGEVY at ASH
Vertex Pharmaceuticals (VRTX) announced longer-term data for CASGEVY from global clinical trials in people with severe sickle cell disease or transfusion-dependent beta thalassemia. CASGEVY is the ...